May 2022
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
"Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic areas
Kallyope, pioneers in drug discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares compound library for its industry-leading biology platform to identify potential GPCR targets and advance the development of new gastrointestinal therapeutics
Tokyo, Japan, Cambridge, UK and New York, USA – May 17, 2022 – Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases. "